
## José Claudio Casali-da-Rocha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3275669/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 2005, 105, 4752-4758.	1.4	205
2	The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Letters, 2007, 245, 96-102.	7.2	170
3	hMLH1 and hMSH2 Gene Mutation in Brazilian Families With Suspected Hereditary Nonpolyposis Colorectal Cancer. Annals of Surgical Oncology, 2002, 9, 555-561.	1.5	24
4	Genetic Landscape of Male Breast Cancer. Cancers, 2021, 13, 3535.	3.7	22
5	Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation. Familial Cancer, 2010, 9, 635-642.	1.9	19
6	Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience, 2017, 11, 716.	1.1	16
7	Biobanking for health research in Brazil: present challenges and future directions. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2012, 31, 523-528.	1.1	16
8	The Influences of Adherence to Tamoxifen and <i>CYP2D6</i> Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)â€Endoxifen in Breast Cancer. Clinical and Translational Science, 2020, 13, 284-292.	3.1	14
9	Clinical and Molecular Assessment of Patients with Lynch Syndrome and Sarcomas Underpinning the Association with MSH2 Germline Pathogenic Variants. Cancers, 2020, 12, 1848.	3.7	14
10	Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer. International Journal of Gynecology and Obstetrics, 2010, 109, 113-117.	2.3	12
11	The Human Face of Biobank Networks for Translational Research. Biopreservation and Biobanking, 2011, 9, 279-285.	1.0	12
12	Malignant Phyllodes Tumor of the Breast: A Practice Review. Clinics and Practice, 2021, 11, 205-215.	1.4	10
13	Serum albumin and vascular endothelial growth factor in epithelial ovarian cancer: looking at adnexal tumor drainage. Archives of Gynecology and Obstetrics, 2011, 283, 855-859.	1.7	9
14	Simulation of the mutation F76del on the von Hippel–Lindau tumor suppressor protein: Mechanism of the disease and implications for drug development. Proteins: Structure, Function and Bioinformatics, 2013, 81, 349-363.	2.6	5
15	Termo de consentimento e análise de material biológico armazenado. Revista Da Associação Médica Brasileira, 2010, 56, 563-567.	0.7	3
16	(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. Journal of Personalized Medicine, 2022, 12, 511.	2.5	3
17	Response to "Germline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni-like syndromeâ€ <del>,</del> by Ribeiro et al Cancer Letters, 2007, 247, 356-358.	7.2	1
18	When guidelines face reality — Lynch syndrome screening in the setting of public health system in a developing country. Journal of Community Genetics, 2022, 13, 19-29.	1.2	1

#	Article	IF	CITATIONS
19	Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers. Cancers, 2022, 14, 3014.	3.7	1
20	Abstract 3991: ONCOTARGET (ONCOALVO): A custom NGS panel for therapeutic decision in solid tumors refractory to conventional therapy. , 2019, , .		0
21	Abstract P1-07-08: Endoxifen predicts early recurrence in breast cancer: A Brazilian prospective study. Cancer Research, 2022, 82, P1-07-08-P1-07-08.	0.9	0